Evidence map›Paper›PMID 41135832›Full record

ArticleJournal of substance use and addiction treatment2025

Implementation outcomes included in NIDA Clinical Trials Network (CTN) studies: A systematic review of studies conducted over 20 years.

Sophia T Gonzalez, Viviana E Horigian, Hannah Cheng, Hildi J Hagedorn, Dikla Shmueli-Blumberg, Cynthia I Campbell, Chunqing Lin, Erin Rogers, Jure Baloh, Rachel Hilton and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of substance use and addiction treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sophia T GonzalezDepartment of Public Health Sciences, University of Miami Miller School of Medicine, 1120 NW 14th, Miami, FL, 33136, USA. Electronic address: stg46@miami.edu.
Viviana E HorigianDepartment of Public Health Sciences, University of Miami Miller School of Medicine, 1120 NW 14th, Miami, FL, 33136, USA.
Hannah ChengStanford Center for Dissemination and Implementation, Department of Psychiatry & Behavioral Sciences, Stanford University School of Medicine, 1070 Arastradero Road, Palo Alto, CA, 94304-5590, USA; Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, 625 N Michigan Ave, Chicago, IL, 60611, USA.
Hildi J HagedornCenter for Chronic Disease Outcomes Research, Minneapolis VA Health Care System & Department of Psychiatry, University of Minnesota School of Medicine, Minneapolis, MN, USA.
Dikla Shmueli-BlumbergRho, Inc., Chapel Hill, NC, USA.
Cynthia I CampbellDivision of Research, Kaiser Permanente Northern California, 1 Kaiser Plaza, Oakland, CA, 94612, USA.
Chunqing LinDepartment of Psychiatry and Biobehavioral Sciences, Center for Community Health, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, 10920 Wilshire Blvd., Suite 350, Los Angeles, CA, 90024, USA.
Erin RogersDepartment of Population Health, Grossman School of Medicine, New York University, 180 Madison Avenue, New York, NY, 10016, USA.
Jure BalohDepartment of Health Policy & Management, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Rachel HiltonVanderbilit University, Nashville, TN, USA.
Ashley VenaEmmes Corporation, 401 N Washington St., Rockville, MD, 20850, USA.
Jennifer McNeelyDepartment of Population Health, Grossman School of Medicine, New York University, 180 Madison Avenue, New York, NY, 10016, USA.
Joseph E GlassChestnut Health Systems, Eugene, OR 97401, USA.

Funding

Project-003UG1DA013035 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aimee N Campbell, Jennifer McNeely · 2015 to 2026
$130.3M
The Florida Node Alliance of the National Drug Abuse Treatment Clinical Trials NetworkUG1DA013720 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Daniel J Feaster, Viviana Elizabeth Horigian · 2015 to 2026
$50.6M
Project-002UG1DA040314 · NIDA · KAISER FOUNDATION RESEARCH INSTITUTE · PI Ingrid A Binswanger, CYNTHIA I CAMPBELL · 2015 to 2026
$34.9M
Transforming health equity rhetoric to rigor: Development and validation of a novel measure assessing health equity in implementation of health interventionsP50DA054072 · NIDA · STANFORD UNIVERSITY · PI Sara Becker · 2022 to 2026
$18.1M
Institutional Career DevelopmentKL2TR003108 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI ARTHUR, JOHN M., BORSHEIM, ELISABET · 2019 to 2023
$2.3M
NCATS NIH HHS KL2 TR003108NIDA NIH HHS P50 DA054072NIDA NIH HHS UG1 DA013035NIDA NIH HHS UG1 DA013720NIDA NIH HHS UG1 DA040314
6 · The paper itself

Abstract

backgroundThe National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN) has supported clinical trials of substance use disorder (SUD) interventions for 25 years. This review describes the use of implementation outcomes across CTN trials, characterizes outcomes included, and identifies gaps and potential opportunities to strengthen implementation research within the CTN and the field of SUD treatment.

methodsThis systematic review included active or completed studies listed on the CTN Dissemination Library webpage as of August 18, 2021, and approved by the CTN for development by January 1, 2022. Study summaries and protocols were reviewed if they: 1) measured at least one implementation outcome and 2) examined a practice change, intervention, or process. Extracted data elements included trial design characteristics, implementation frameworks, and outcome assessment domains informed by the RE-AIM and Proctor Implementation Outcomes Frameworks.

results114 protocols were considered, 42 full-text protocols were screened, and 25 were included for data extraction. Start dates of trials spanned a 20-year period (2004-2024) with latter studies including more implementation outcomes. Fidelity (n = 29) and reach/penetration (n = 26) were the most included implementation outcomes. Equity was not identified in any protocols. Methods of defining, capturing, and evaluating outcomes data varied across trials and outcomes.

conclusionThe inclusion of implementation outcomes increased over time, perhaps reflecting a growing emphasis on implementation research. Incorporating measures of equity could advance knowledge about differential receipt or effectiveness of SUD interventions. Future research should seek to improve the consistency and comprehensiveness in descriptions of implementation science elements.

Indexed as

Implementation outcomesImplementation scienceSubstance useTreatment

Identifiers

PMID41135832
PMCPMC12785561

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.